Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Ataxia
81%
Levetiracetam
71%
Friedreich's Ataxia
56%
Motor Dysfunction
45%
Placebo
42%
Essential Tremor
40%
Varenicline
40%
Spinocerebellar Degeneration
39%
Chorea
26%
Syndrome
24%
Levodopa
23%
Constipation
23%
Solifenacin
20%
Overactive Bladder
20%
Levodopa-Induced Dyskinesia
20%
Huntington Chorea
20%
Prevalence
17%
Tegaserod
15%
Immunoglobulin
15%
Vatiquinone
15%
Disease Exacerbation
15%
Hyperhomocysteinemia
12%
Mood Disorder
10%
Disease Duration
10%
Sodium Valproate
10%
Glutamine
10%
Zonisamide
10%
Biological Marker
10%
Glutamic Acid
10%
Coronavirinae
10%
Cognitive Defect
10%
Snoring
10%
Prostate Cancer
10%
Breast Cancer
10%
Uterine Cervix Cancer
10%
Congenital Malformation
10%
Teratogenesis
10%
Enuresis
9%
Side Effect
9%
Dyskinesia
9%
Dystonia
8%
Oxidoreductase
8%
Lamictal
8%
Propranolol
8%
Folic Acid
7%
Botulinum Toxin A
7%
Pregabalin
7%
Open-Label Trial
7%
Weakness
6%
Medicine and Dentistry
Parkinson's Disease
96%
Essential Tremor
50%
Stereotypic Movement Disorder
31%
Placebo
27%
Deep Brain Stimulation
21%
Solifenacin
20%
Overactive Bladder
20%
Chorea
18%
Sleep Time
16%
Friedreich's Ataxia
15%
Levodopa
15%
COVID-19
15%
Zonisamide
15%
Community-Dwelling Older Adults
15%
Body Mass Index
15%
Psychological Trauma
15%
Levetiracetam
13%
Prevalence
13%
Constipation
13%
Side Effect
12%
Cervical Cancer
12%
Breast Cancer
11%
Topiramate
10%
Symptom
10%
Ataxia
10%
Hyperhomocysteinemia
10%
Military Health
10%
Cardiovascular System
10%
Varenicline
10%
Mammography
10%
Tegaserod
10%
Prostate Cancer
10%
Sodium Valproate
10%
Teratogenesis
10%
Congenital Malformation
10%
Epileptic Seizure
10%
Enuresis
9%
Behavioral Risk Factor Surveillance System
9%
Lamotrigine
8%
Limb Tremor
7%
Gabapentin
7%
Propranolol
7%
Health Care Cost
7%
Offspring
6%
Folic Acid
6%
Neural Tube Defect
6%
Supplementation
6%
Accelerometry
6%
Unified Parkinson's Disease Rating Scale
6%
Meta-Analysis
6%
Nursing and Health Professions
Parkinson's Disease
60%
Friedreich's Ataxia
50%
Sleep Time
32%
Essential Tremor
20%
Overactive Bladder
20%
Solifenacin
20%
Logistic Regression Analysis
17%
Behavioral Risk Factor Surveillance System
17%
Ataxia
17%
Medicare
15%
Congestive Heart Failure
15%
Gait Analysis System
13%
Independent Practice Association
12%
Prevalence
11%
Household
11%
Disease Duration
11%
Syndrome
11%
Papanicolaou Test
11%
Berg Balance Scale
10%
Placebo
10%
Mammography
10%
Body Weight
10%
Heart Disease
10%
Racial Group
10%
Cigarette Filter
10%
Adolescent
10%
Enuresis
9%
Walking Speed
9%
Rating Scale
7%
Motor Dysfunction
6%
Effect Size
6%
Mood Disorder
6%
Cognitive Defect
6%
Correlation Coefficient
6%
Sleep Disorder
6%
Side Effect
6%
Stride Length
6%
Nocturia
5%
Pilot Study
5%
Urinary Dysfunction
5%
Step Length
5%
Electrical Brain Stimulation
5%
Deprescribing
5%
Arthritis
5%
Meta Analysis
5%
Ethnic Group
5%
Tiagabine
5%
Psychological Trauma
5%
Nutrition Supplement
5%
Zonisamide
5%
